John Edwards Email & Phone Number

Executive Chair, board member, and senior adviser to start-up and clinical-stage biotechnology companies. I often work with the CEO and board to advance a company's strategic direction and positioning for the next stage in its evolution. Together with the CEO, I often play a significant role in financing and business development, as well as in product.

Austin, Texas, US

PanTher Therapeutics is a clinical-stage oncology company offering transformational localized treatment of cancer. This is accomplished through its platform which enables continuous, high-dose treatment of potent oncology agents exclusively at the site of a tumor. PanTher’s lead clinical candidate, PTM-101, has successfully been evaluated in a Phase 1.

Boston, Massachusetts, US

Strand Therapeutics is a clinical-stage biotechnology company utilizing synthetic biology to genetically program mRNA to deliver truly revolutionary therapies.I provide drug development, business development, and financing-related support to Strands senior team, including participating in all board meetings.

Bedford, Massachusetts, US

Verseau is focused on developing immunotherapies directed at broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accomplished by stimulating macrophages to shift their phenotype from immunosuppressive to a pro-inflammatory, anti-tumor state in a process called macrophage repolarization. Verseau developed a unique target.

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications that are modulated by cytotoxic T and NK cells. The company’s platform is based on targeting KLRG1 (killer cell lectin-like receptor G), which is a receptor that evolved as the body’s control switch for the most cytotoxic T and NK cells. Abcuro has.

Cambridge, MA, US

Metera Pharmaceuticals was founded on the vision of making a major difference in serious respiratory diseases. In 2018, Metera completed a license agreement with RespiVert, a wholly-owned subsidiary of Janssen Biotech, to develop and commercialize novel therapies for severe respiratory diseases. This license led to the creation of Metera’s lead program.

Cambridge, Cambridgeshire, GB

Cambridge, Cambridgeshire, GB

Working with the board and CEO we effectively transitioned F-star from a technology-focused discovery company into a clinical-stage, product-focused research and development organization, with a significant emphasis in the area of immuno-oncology. I helped build the development team and strategy, put in place a senior management team, and grew the company.

Tilos Therapeutics was founded in 2016 based on research on LAP (latency-associated peptide of TGFβ) at Brigham and Women’s Hospital. The company was focused on developing new therapies for the treatment of cancer, fibrosis, and related disorders.While working with the CEO to complete a Series A financing, we were able to attract Merck's interest in our.

Siamab Therapeutics was a biopharmaceutical company focused on developing novel tumor-associated carbohydrate antigen cancer therapies. I supported the CEO and board to help build Siamab, which lead to a discovery collaboration with Boehringer Ingelheim in 2017 and a successful exit for the company with the sale of its lead program in 2019 to Seagen valued.

Exonics Therapeutics was launched in 2017 to develop treatments for patients with neuromuscular diseases based on the work of its scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center. I worked with the board to pull together the company positioning, strategy, and senior team. We then completed a.

Lexington, Massachusetts, US

ImmuneXcite was a biopharmaceutical company developing a broadly applicable immuno-oncology platform that utilized the power of both the innate and adaptive immune system. The technology was based on ImmuneXcite’s research, which identified a unique fungal carbohydrate that can be used in conjunction with a tumor-targeted antibody to mount a potent attack.

Lawrence Township, NJ, US

Successfully led the transition of Adnexus from a private biotech company to a wholly-owned subsidiary of BMS. Transformed our technology and operational efficiency, while increasing our portfolio from 3 to 20 ongoing discovery programs within a company of only 100 employees. This led to at least 1 new product IND filing each year post-acquisition. In.

Lawrence Township, NJ, US

Responsible for playing a leadership role in building Adnexus, which included three rounds of venture financing (Atlas, Flagship, Polaris, and Venrock) and advancing the lead program into the clinic. In 2007 Adnexus was acquired for $450M by BMS, representing a >8x return in less than 4 years.

Tokyo, JP, JP

Responsible for North American sales, marketing, and medical affairs. This included all pre-launch planning, hiring the sales force and MSLs, and conducting phase IV clinical studies for Replagal (Fabry disease), as well as program leadership and commercial planning for Elaprase (Hunter syndrome). The company went on to be sold to Shire for $1.6B in 2005.

I led the effort to build a global biopharmaceutical business in hematology at Genetics Institute/Wyeth, which represented Genetics Institute’s most successful business unit in its 20-year history (peak sales eventually reached >$1B).I also led the global commercial launches of four biopharmaceuticals: two hematology products (BeneFIX, ReFacto), one.

Responsible for leading Genetics Institute’s first approved product, BeneFIX (recombinant factor IX), from discovery, into clinical trials, and through regulatory approvals, which included being the first product in our industry to file for simultaneous approval in US and Europe using the Common Technical Document. We established the biopharmaceutical.

Responsible for establishing and then managing Genetics Institute’s Andover and Cambridge, Massachusetts pilot, clinical, as well as commercial-scale manufacturing operations, which produced products such as EPO, Factor VIII (Recombinate), and BMP-2 (Infuse).

Paris, France, FR

One of the first 20 employees at Genzyme in Boston. I was one of the original scientists involved in the hyaluronic acid program, which eventually led to the development of the FDA approved drug, Synvisc.

Mba, Marketing

Bs, Chemical Engineering